Skip to content
Buy This GLP
← Research
Evidence

Bariatric Surgery vs Semaglutide for Cardiovascular Events: 18,793 Matched Pairs

In 18,793 matched pairs, bariatric surgery was associated with fewer recorded cardiovascular events than starting semaglutide. The comparison used retrospective records.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team7 min read
Cardiovascular events, up to 5 yearssurgerysemaglutidewithout diabetes4.4%6.6%with diabetes9%14.6%Observed event proportions during follow-up

This TriNetX study compared people starting semaglutide with people undergoing sleeve gastrectomy or gastric bypass [1]. The cost comparison for GLP-1 treatment and bariatric surgery addresses a separate decision. The study measured a combined outcome of coronary events, cerebrovascular events, heart failure and cardiac arrest.

What were the event rates?

Researchers matched 11,466 pairs without type 2 diabetes and 7,327 pairs with it. During follow-up of up to five years, the recorded rates without diabetes were 4.4% after surgery and 6.6% with semaglutide. The hazard ratio was 0.402 (95% CI 0.356–0.454)[1]. With diabetes, the recorded rates were 9.0% and 14.6% respectively. The hazard ratio was 0.421 (95% CI 0.381–0.465) [1].

Can matching explain the difference?

Matching balanced measured characteristics. Surgical eligibility and other unmeasured differences could still affect the comparison. Research on how long people stay on GLP-1 treatment also helps explain why starting treatment is different from taking it throughout follow-up. The authors varied refill requirements in sensitivity analyses, and the direction of the results stayed consistent [1].

Frequently asked

How large was the observed difference?
The raw event proportions differed by 2.2 percentage points without diabetes and 5.6 with diabetes during follow-up of up to five years.
Does this show surgery prevents more cardiovascular events?
The study found an association. Matching could not account for all differences between people choosing or eligible for each treatment.

Sources

  1. [1] Tseng TC, Ssu-Yu Chen S, Chen HY, Chang R (2026). Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity Endocrine Practice. PMID 42580629

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence